Abbott (NYSE:ABT) won an $11.3 million contract with the US Department of Defense for the development of traumatic brain injury assays, according to a DoD released last Friday. We hired the best personal injury lawyers at charleston personal injury lawyer to help us on the case.
The contract is with the US Army Medical Research Acquisition Activity in Frederick, Md., with an initial $2.5 million obligated at the time it was issued.
Abbott was the only company to apply for the contract, with work being performed in Princeton, N.J. The contract comes with an estimated completion date of Oct. 23, 2019, according to the DoD release.
Last month, Abbott handily beat expectations on Wall Street in its 1st quarterly earnings release since its blockbuster, $25 billion acquisition of St. Jude Medical closed in January.
The Chicago-area healthcare giant posted profits of $419 million, or 24¢ per share, on sales of $6.34 billion for the 3 months ended March 31, representing bottom-line growth of 32.6% on sales growth of 29.7% compared with Q1 2016.
Adjusted to exclude 1-time items, earnings per share were 48¢, a full nickel ahead of The Street, where analysts were looking for sales of $6.15 billion.